Report error Found 35 Enz. Inhib. hit(s) with all data for entry = 8922
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 100nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 550nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 550nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 550nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 550nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 550nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 550nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 550nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 14(Human)
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:Experimental Method: 40 nM p38a was added into a reaction buffer, which include 20 mM HEPES (4-hydroxyethylpiperazine ethanesulfonic acid), 5 mM MgCl...More data for this Ligand-Target Pair
Affinity DataIC50: 2.00E+4nMAssay Description:Experimental Method: 4-hydroxydiclofenac (the substrate for CYP450 and 2C9 enzymes) and different doses of compounds were added into human liver micr...More data for this Ligand-Target Pair
Affinity DataIC50: 5.00E+4nMAssay Description:Experimental Method: 4-hydroxydiclofenac (the substrate for CYP450 and 2C9 enzymes) and different doses of compounds were added into human liver micr...More data for this Ligand-Target Pair
Affinity DataIC50: 5.00E+4nMAssay Description:Experimental Method: 4-hydroxydiclofenac (the substrate for CYP450 and 2C9 enzymes) and different doses of compounds were added into human liver micr...More data for this Ligand-Target Pair
Affinity DataIC50: 5.00E+4nMAssay Description:Experimental Method: 4-hydroxydiclofenac (the substrate for CYP450 and 2C9 enzymes) and different doses of compounds were added into human liver micr...More data for this Ligand-Target Pair
Affinity DataIC50: 5.00E+4nMAssay Description:Experimental Method: 4-hydroxydiclofenac (the substrate for CYP450 and 2C9 enzymes) and different doses of compounds were added into human liver micr...More data for this Ligand-Target Pair
Affinity DataIC50: 5.00E+4nMAssay Description:Experimental Method: 4-hydroxydiclofenac (the substrate for CYP450 and 2C9 enzymes) and different doses of compounds were added into human liver micr...More data for this Ligand-Target Pair
Affinity DataIC50: 5.00E+4nMAssay Description:Experimental Method: 4-hydroxydiclofenac (the substrate for CYP450 and 2C9 enzymes) and different doses of compounds were added into human liver micr...More data for this Ligand-Target Pair
Affinity DataIC50: 5.00E+4nMAssay Description:Experimental Method: 4-hydroxydiclofenac (the substrate for CYP450 and 2C9 enzymes) and different doses of compounds were added into human liver micr...More data for this Ligand-Target Pair
Affinity DataIC50: 5.00E+4nMAssay Description:Experimental Method: 4-hydroxydiclofenac (the substrate for CYP450 and 2C9 enzymes) and different doses of compounds were added into human liver micr...More data for this Ligand-Target Pair
Affinity DataIC50: 5.00E+4nMAssay Description:Experimental Method: 4-hydroxydiclofenac (the substrate for CYP450 and 2C9 enzymes) and different doses of compounds were added into human liver micr...More data for this Ligand-Target Pair
Affinity DataIC50: 5.00E+4nMAssay Description:Experimental Method: 4-hydroxydiclofenac (the substrate for CYP450 and 2C9 enzymes) and different doses of compounds were added into human liver micr...More data for this Ligand-Target Pair
